Completed phase I/IIa clinical trial
Twenty-seven patients participated in phase I/IIa clinical trials conducted in 4 different clinical centers in Eurasia.
A high degree of safety was demonstrated in dose escalation studies.
Three groups of five patients each were administered escalating doses of Elenagen. Only minimal Grade I side effects were observed in some patients.
Elenagen was able to reduce and outright cease disease progression
in patients with melanoma, breast, ovary, lung, and renal cancer. Patients admitted into our trial were “salvage patients” who have failed all other available treatment protocols and were in the active disease progression stage. The main goal was to stop the disease progression, which we have achieved.
Restoring tumor sensitivity to chemotherapy.
All patients admitted to the clinical trials already failed multiple previous lines of chemotherapy. However, after treatment with Elenagen, the patients were able to successfully respond to new rounds of chemotherapy.